ReviewCurrent neurology and neuroscience reports2023
Paraneoplastic Neurologic Disorders.
Review in Current neurology and neuroscience reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Paraneoplastic Neurological Syndromes in Ovarian Cancer: Case Report and Narrative Review for Diagnostic and Clinical Implications.Healthcare (Basel, Switzerland) · 2026Review
- Paraneoplastic Cerebellar Degeneration Due to Tonsillar Cancer; A Case Series.Cerebellum (London, England) · 2026Article
- Long-Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy-A 10-Year Follow Up Study.Annals of clinical and translational neurology · 2026Article
- Novel methods for neural IgG characterization and validation in autoimmune neurologic disorders.Journal of immunological methods · 2026Review
- Anti-KLHL11 antibody encephalitis without detectable malignancy: a case report and literature review.Frontiers in immunology · 2026Review
- Cancer-related movement disorders: A scoping review and diagnostic approach.Neuro-oncology practice · 2025Review
- Mechanisms of cancer-induced neurophysiological dysfunction and therapeutic strategies.Discover oncology · 2025Review
- Indications and Diagnostic Yield of Paraneoplastic and Autoimmune Encephalitis Antibody Testing: A Retrospective Cohort Study.Brain and behavior · 2025Article
- Anti-kelch-like protein 11 antibody-associated encephalitis: two case reports and literature review.BMC neurology · 2025Review
- CNS manifestations in acute and chronic graft-versus-host disease.Brain : a journal of neurology · 2025Article
- Protracted Presentation of Anti-LGI 1 Encephalitis Associated with Prostate Cancer: A Case Report.Movement disorders clinical practice · 2025Article
- Late-onset anti-Yo antibody-positive paraneoplastic cerebellar degeneration: a case report.Frontiers in surgery · 2025Article
- Editorial: Neuro-immune interplay: unraveling the complexities of neurological complications and immunology.Frontiers in molecular neuroscience · 2025Article
- Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.Frontiers in immunology · 2025Article
- Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria.Annals of clinical and translational neurology · 2025Article
- Autoimmune Encephalitis in a Patient with a Solitary Intracranial Plasmacytoma.Internal medicine (Tokyo, Japan) · 2024Article
- Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.Annals of neurology · 2024Article
- Identification of DAGLA as an autoantibody target in cerebellar ataxia.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- A Systematic Review of Sporadic Creutzfeldt-Jakob Disease: Pathogenesis, Diagnosis, and Therapeutic Attempts.Neurology international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewTo provide an overview and highlight recent updates in the field of paraneoplastic neurologic disorders. RECENT
findingsThe prevalence of paraneoplastic neurologic disorders is greater than previously reported and the incidence has been rising over time, due to improved recognition in the era of antibody biomarkers. Updated diagnostic criteria that are broadly inclusive and also contain diagnostic risk for clinical presentations (high and intermediate) and diagnostic antibodies (high, intermediate, and low) have replaced the original 2004 criteria. Antibody biomarkers continue to be characterized (e.g., KLHL-11 associated with seminoma in men with brainstem encephalitis). Some paraneoplastic antibodies also provide insight into likely immunotherapy response and prognosis. The rise of immune checkpoint inhibitors as cancer therapeutics has been associated with newly observed immune-mediated adverse effects including paraneoplastic neurological disorders. The therapeutic approach to paraneoplastic neurologic disorders is centered around cancer care and trials of immune therapy. The field of paraneoplastic neurologic disorders continues to be advanced by the identification of novel antibody biomarkers which have diagnostic utility, and give insight into likely treatment responses and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.